Smac类似物Birinapant的抗肝癌作用及相关分子机制

doi:10.12047/j.cjap.5685.2018.117

中国应用生理学杂志 ›› 2018, Vol. 34 ›› Issue (6): 524-529.doi: 10.12047/j.cjap.5685.2018.117

Smac类似物Birinapant的抗肝癌作用及相关分子机制

蒋盼若, 柯瑞君, 朱明了, 楼恩哲, 谢佳庚, 陈佳玉

绍兴文理学院医学院, 浙江绍兴 312000

收稿日期:2018-03-12 修回日期:2018-11-14 出版日期:2018-11-28 发布日期:2019-03-09
通讯作者: 陈佳玉 E-mail:chenkc1969@163.com
基金资助:
国家自然科学基金资助项目（81402979）；浙江省科技厅资助项目（2015C33270）；浙江省卫生厅资助项目（2014KYA230）；国家大学生创新创业训练计划项目（201810349028）；浙江省大学生科技创新活动计划项目（2018R432016）；绍兴市大学生创新项目（SXSDC201709）

Anti-hepatoma effects of Smac analogue Birinapant and its related molecular mechanism

JIANG Pan-ruo, KE Rui-jun, ZHU Ming-liao, LOU En-zhe, XIE Jia-geng, CHEN Jia-yu

Medical School, Shaoxing University, Shaoxing 312000, China

Received:2018-03-12 Revised:2018-11-14 Online:2018-11-28 Published:2019-03-09
Supported by:
国家自然科学基金资助项目（81402979）；浙江省科技厅资助项目（2015C33270）；浙江省卫生厅资助项目（2014KYA230）；国家大学生创新创业训练计划项目（201810349028）；浙江省大学生科技创新活动计划项目（2018R432016）；绍兴市大学生创新项目（SXSDC201709）

摘要/Abstract

摘要： 目的：探讨Birinapant抗肝癌的作用及分子机制。方法：人肝癌细胞QGY-7701经终浓度为0、1、5、25和125 nmol/L的Birinapant作用24、48和72 h，各设3个复孔，检测细胞增殖活性，分析细胞凋亡率，观察细胞核型和线粒体膜电位变化，分析基因转录与表达水平，评价药物细胞毒性；同时，将4周龄雄性BALB/C小鼠随机分成5组，每组20只，腹股沟注射肝癌细胞QGY-7701，两天后各组皮下分别注射Birinapant（0、1、5、25和125 μg/kg），隔天注射一次，首次注射Birinapant后18 d，每组脱颈处死10只小鼠，取瘤组织称重，并记录各组剩余10只小鼠的存活期，观察Birinapant对荷瘤小鼠肝癌生长及生存期的影响。结果：与对照组（NC）比较，Birinapant处理组的细胞增殖显著受抑制、细胞凋亡率显著增加（P<0.01），出现细胞线粒体膜电位降低及核型改变，同时细胞内cIAP-1（cellular inhibitor of apoptosis protein 1）、cIAP-2（cellular inhibitor of apoptosis protein 2）、ras、raf、mek、erk基因的表达显著下调（P<0.01），caspase-3和caspase-9基因的表达水平显著上调（P<0.01）；与模型对照组（MG）比较，Birinapant处理组的荷瘤小鼠瘤组织生长速度显著减小且生存期延长（P<0.01）。结论：Birinapant通过抑制cIAP-1、cIAP-2和Ras-Raf-MEK-ERK通路蛋白的表达，激活线粒体介导的内源性凋亡，对肝癌有一定的抑制作用。

关键词: 肝癌, Smac类似物, Birinapant, 增殖, 凋亡, 小鼠

Abstract: Objective: To investigate the effects of Birinapant on hepatocellular carcinoma cells and its related molecular mechanisms.Methods: Human hepatocellular carcinoma cells QGY-7701 were treated with 0, 1, 5, 25 and 125 nmol/L Birinapant for 24, 48 and 72 hours respectively, each experiment 3 wells.The proliferation activity of cells, the apoptosis levels, the cells nuclear type, the mitochondrial membrane potential, the transcription and expression levels of genes and the cytotoxicity of Birinapant were analyzed.At the same time, 4-week-old male BALB/C mice were randomly divided into 5 groups, with 20 mice in each group.The mice were inguinal injected with QGY-7701 cells, and then subcutaneous injected with Birinapant (concentrations ranging from 0, 1, 5, 25, 125 μg/kg) in each group after two days, once every other day.On 18^th day since first Birinapant injection, 10 mice were killed in each group to weigh tumor tissue and survival time was recorded from the remaining 10 mice.The effects of Birinapant on the growth of the tumor and the survival time of tumor-bearing mice were observed.Results: Compared with the negative control (NC) group, the proliferation activity of QGY-7701 was inhibited significantly after Birinapant treatment and the apoptosis levels were increased significantly (P<0.01).The cell mitochondrial membrane potential was decreased and the karyotype was changed (P<0.01).At the same time, the transcription and expression levels of genes cellular inhibitor of apoptosis protein 1(cIAP-1), cellular inhibitor of apoptosis protein 2(cIAP-2), ras, raf, mek and erk were significantly decreased (P<0.01), while the expression levels of caspase-3 and caspase-9 genes were up-regulated (P<0.01).Compared with the model group (MG), the growth of the tumor was inhibited significantly and the survival time of the tumor-bearing mice was prolonged after Birinapant treatment (P<0.01).Conclusion: Birinapant can inhibit the expression of cIAP-1, cIAP-2 and the proteins of Ras-Raf-MEK-ERK signal pathways, so as to activate the mitochondria mediated endogenous apoptosis pathway.Birinapant shows a certain inhibitory effect on liver cancer.

Key words: liver cancer, Smac analogue, Birinapant, proliferation, apoptosis, mice

蒋盼若, 柯瑞君, 朱明了, 楼恩哲, 谢佳庚, 陈佳玉. Smac类似物Birinapant的抗肝癌作用及相关分子机制[J]. 中国应用生理学杂志, 2018, 34(6): 524-529.

JIANG Pan-ruo, KE Rui-jun, ZHU Ming-liao, LOU En-zhe, XIE Jia-geng, CHEN Jia-yu. Anti-hepatoma effects of Smac analogue Birinapant and its related molecular mechanism[J]. CJAP, 2018, 34(6): 524-529.

参考文献

[1] Global Burden of Disease Liver Cancer Collaboration, Akinyemiju T, Abera S, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level:results from the global burden of disease study 2015[J]. JAMA Oncol, 2017, 3(12):1683-1691.
[2] Singh B, Jang Y, Maharjan S, et al. Combination therapy with doxorubicin-loaded galactosylated poly (ethyleneglycol)-lithocholic acid to suppress the tumor growth in an orthotopic mouse model of liver cancer[J]. Biomaterials, 2017, 116:130-144.
[3] 高园, 聂鸿靖, 杨栋, 等. 肝癌患者单个核细胞线粒体DNA拷贝数与抗氧化能力的变化[J]. 中国应用生理学杂志, 2016, 32(1):1-5.
[4] Ebert G, Allison C, Preston S, et al. Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis[J]. Proc Natl Acad Sci U S A, 2015, 112(18):5803-5808.
[5] Carter BZ, Mak PY, Mak DH, et al. Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents[J]. J Natl Cancer Inst, 2014, 106(2):djt440.
[6] Krepler C, Chunduru SK, Halloran MB, et al. The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells[J]. Clin Cancer Res, 2013, 19(7):1784-1794.
[7] Allensworth JL, Sauer SJ, Lyerly HK, et al. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP dependent and TNF-α independent mechanism[J]. Breast Cancer Res Treat, 2013, 137(2):359-371.
[8] Sarosiek KA, Fraser C, Muthalagu N, et al. Developmental regulation of mitochondrial apoptosis by c-Myc governs age-and tissue-specific sensitivity to cancer therapeutics[J]. Cancer Cell, 2017, 31(1):142-156.
[9] Elsayed NMY, Abou El Ella DA, Serya RAT, et al. Targeting apoptotic machinery as approach for anticancer therapy:Smac mimetics as anticancer agents[J]. Future J Pharmaceutical Sciences, 2015, 1(1):16-21.
[10] Fulda S.Smac mimetics to therapeutically target IAP proteins in cancer[J]. Int Rev Cell Mol Biol, 2017, 330:157-169.
[11] Cai J, Lin Y, Zhang H, et al. Selective replication of oncolytic virus M1 results in a bystander killing effect that is potentiated by Smac mimetics[J]. Proc Natl Acad Sci U S A, 2017, 114(26):6812-6817.
[12] Srivastava AK, Jaganathan S, Stephen L, et al. Effect of a Smac Mimetic (TL32711, Birinapant) on the apoptotic program and apoptosis biomarkers examined with validated multiplex immunoassays fit for clinical use[J]. Clin Cancer Res, 2016, 22(4):1000-1010.
[13] Nguyen QD, Lavdas I, Gubbins J, et al. Temporal and spatial evolution of therapy induced tumor apoptosis detected by caspase-3-selective molecular imaging[J]. Clin Cancer Res, 2013, 19(14):3914-3924.
[14] 黄林静, 张聪聪, 赵美平, 等. MAPK信号通路对大鼠低氧性PASMCs增殖、凋亡的调控[J]. 中国应用生理学杂志, 2017, 33(3):226-230.
[15] Maik-Rachline G, Seger R.The ERK cascade inhibitors:Towards overcoming resistance[J]. Drug Resist Updat, 2016, 25:1-12.
[16] Suzuki R, Kikuchi S, Harada T, et al. Combination of a selective HSP90α/β inhibitor and a RAS-RAF-MEK-ERK signaling pathway inhibitor triggers synergistic cytotoxicity in multiple myeloma cells[J]. Plos One, 2015, 10(12):e0143847.
[17] Butler DE, Marlein C, Walker HF, et al. Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer[J]. Oncotarget, 2017, 8(34):56698-56713.
[18] Burdeos GC, Ito J, Eitsuka T, et al. δ and γ tocotrienols suppress human hepatocellular carcinoma cell proliferation via regulation of Ras-Raf-MEK-ERK pathway-associated upstream signaling[J]. Food Funct, 2016, 7(10):4170-4174.

Smac类似物Birinapant的抗肝癌作用及相关分子机制

Anti-hepatoma effects of Smac analogue Birinapant and its related molecular mechanism

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	邵小婷, 扈敬, 张欣颖, 赵冰冰, 李思葳, 高萍, 徐长庆, 魏璨. 外源性精胺对糖尿病肾病小鼠肾纤维化的影响及其机制[J]. 中国应用生理学杂志, 2020, 36(3): 207-210.
[2]	刘凯丽, 都新新, 张文琴, 吴亚俐, 王茜, 王春芳, 崔香丽. 过表达miR-31对结肠炎模型小鼠TLR4/NF-κB信号通路及凋亡蛋白的调控[J]. 中国应用生理学杂志, 2020, 36(3): 211-215.
[3]	卢林明, 俞婷婷, 何晓伟, 汤娟, 李先伟. 小剂量辣椒素抗小鼠肺纤维化的作用及其机制[J]. 中国应用生理学杂志, 2020, 36(3): 216-222.
[4]	姜洪波, 董家行, 秦玉飞, 刘佳聪, 姜万举, 李若男, 刘岚慈, 田一丹, 许予明, 杜爱林. 硫氢化钠对脊髓小脑共济失调3型小鼠海马MBP及学习记忆的影响[J]. 中国应用生理学杂志, 2020, 36(3): 235-239.
[5]	方振, 胡西厚, 李康, 韩洁, 田蕾, 闫峻, 张伟, 来文庆, 林本成, 刘晓华, 袭著革. PM_2.5鼻腔滴注致小鼠海马组织损伤的炎性机制[J]. 中国应用生理学杂志, 2020, 36(3): 240-244.
[6]	陈宇峰, 董凡赫, 楼云玮, 寿今豪, 张慧婷, 周一超, 严明, 毛红娇, 张云. 补骨脂素对TCP磨损颗粒所致大鼠成骨细胞损伤的干预作用及其机制[J]. 中国应用生理学杂志, 2020, 36(3): 255-260.
[7]	王锋, 张海峰. 利拉鲁肽联合维生素D对高脂诱导非酒精性脂肪肝小鼠的影响及机制[J]. 中国应用生理学杂志, 2020, 36(3): 261-264.
[8]	姚楠, 韦凌霞, 王志旺, 丁茂鹏, 付晓艳, 庞亚蓉, 程小丽, 蔺兴遥, 邵晶. 当归对阴虚哮喘小鼠气道黏液高分泌及TNF-α/NF-κB信号通路的影响^*[J]. 中国应用生理学杂志, 2020, 36(2): 97-100.
[9]	霍海燕, 王瑾, 张许梅, 张文婷, 岳继萍, 焦向英. 糖尿病诱导硫氧还蛋白相互作用蛋白(TXNIP)对小鼠胰岛β细胞衰老的影响^*[J]. 中国应用生理学杂志, 2020, 36(2): 119-123.
[10]	罗维, 艾磊, 王博发, 王俐颖, 甘彦明, 周越. 高糖条件下小鼠巨噬细胞对骨骼肌细胞成肌分化和胰岛素敏感性的影响^*[J]. 中国应用生理学杂志, 2020, 36(2): 124-129.
[11]	赵洋, 杨胜昌, 于富洋, 李文雅, 吉恩生. 消痰化瘀利窍方对慢性间歇性低氧小鼠认知障碍的改善作用^*[J]. 中国应用生理学杂志, 2020, 36(2): 143-147.
[12]	梁宛伶, 肖天保, 袁峰, 曹一波, 颜登国. miRNA-95靶向FOXD1基因对结直肠癌LoVo细胞放射敏感性的影响及其机制^*[J]. 中国应用生理学杂志, 2020, 36(2): 148-151.
[13]	罗怡爽, 郑秀婷, 章浩月, 徐丽萍, 裘加鹏, 徐港铭, 刘爱明. α-荼异硫氰酸酯诱导小鼠胆汁淤积性肝纤维化及其炎症通路^*[J]. 中国应用生理学杂志, 2020, 36(2): 152-156.
[14]	杨尊敬, 杜先玲. 细胞周期蛋白依赖性激酶在miR-193a5p调控卵巢癌细胞增殖及上皮细胞间充质转变中的作用^*[J]. 中国应用生理学杂志, 2020, 36(2): 176-179.
[15]	计红, 邵子益, 薛琳琳, 牛春阳, 詹雪龙, 杨闯, 甄莉, 杨焕民, 李士泽. α-烯醇化酶基因干扰表达对籽鹅卵泡颗粒细胞增殖及凋亡的影响^*[J]. 中国应用生理学杂志, 2020, 36(2): 184-188.